Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centanafadine Dose Strength Equivalence Study in Healthy Subjects
NCT07486895Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of centanafadine (2 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Maximum Plasma Concentration, Area Under the Concentration-time Curve Calculated to the Last Observable Concentration at Time t and 1 more. Started Mar 2023; status: completed.
02
Drugs
centanafadine
Beyond the preview
Go deeper on NCT07486895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07486895.